Cantor Fitzgerald Reiterates Overweight Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They currently have a $13.00 price objective on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 142.54% from the company’s current price.

A number of other research firms also recently commented on HUMA. Benchmark restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, September 5th. BTIG Research upped their target price on Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $9.80.

Humacyte Stock Down 1.7 %

Humacyte stock traded down $0.09 during midday trading on Friday, reaching $5.36. The stock had a trading volume of 631,228 shares, compared to its average volume of 2,179,952. The stock has a market capitalization of $638.29 million, a P/E ratio of -5.36 and a beta of 1.47. The firm’s fifty day simple moving average is $6.89 and its 200-day simple moving average is $5.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, analysts expect that Humacyte will post -1.09 EPS for the current fiscal year.

Insider Activity

In related news, Director Brady W. Dougan sold 252,676 shares of Humacyte stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. 23.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HUMA. nVerses Capital LLC bought a new stake in shares of Humacyte during the second quarter worth approximately $28,000. Victory Capital Management Inc. bought a new stake in Humacyte in the 4th quarter valued at $29,000. Principal Financial Group Inc. acquired a new position in Humacyte in the 2nd quarter valued at $83,000. China Universal Asset Management Co. Ltd. increased its position in Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after buying an additional 7,897 shares during the period. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the second quarter worth $97,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.